Takeda's Investigational Compound TAK-491 For Treatment Of Hypertension Enters Into Phase 2 Clinical Stage In The U.S. And Europe

Main Category: Hypertension
Also Included In: Clinical Trials / Drug Trials;  Cardiovascular / Cardiology
Article Date: 17 Jul 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

Osaka, Japan, July 2006 --- Takeda Pharmaceutical Company Limited announced today that its investigational compound TAK-491 has entered into Phase 2 clinical stage in the U.S. and Europe. TAK-491 is an angiotensin receptor blocker (ARB) discovered by Takeda and its mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.

TAK-491 is expected to show stronger anti-hypertensive action, and also to have superior profile in improving the insulin resistance and decreasing proteinuria, as compared to existing ARBs on the market.

"TAK-491 is one of our candidate products which is expected to succeed our current mainstay product, Candesartan, an ARB. " said Masaomi Miyamoto, Ph.D., General Manager of Pharmaceutical Development Division of Takeda. "We will vigorously conduct clinical development of TAK-491 so that we can offer an additional treatment option for patients with hypertension and their physicians as early as possible."

In the anti-hypertensive market, the ARB class is now recognized as a mainstream treatment option. TAK-491, if successfully developed and launched, has the potential to become the most effective member of this important class of drugs, and is expected to support the expansion of the U.S. diabetic franchise of Actos® (generic name; pioglitazone HCl) into Lifestyle-related diseases, and to further enhance the presence in the European cardiovascular market established by Candesartan.

http://www.takeda.com/press/06071101.htm

• Additional
• References
• Citations